Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

Compare with peers Embed
FY2025 at a glance

Sales up 20.2%, free cash flow down to -$472.0M

XBRL, from each 10-K
RevenueStatements
$673.0M from $560.0M in FY2024
FY2016FY2025
Net incomeStatements
-$575.0M from -$569.0M in FY2024
FY2016FY2025
Free cash flowStatements
-$472.0M from -$421.0M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-5.83 from $-6.29 in FY2024
FY2016FY2025
Operating marginStatements
-79.5% from -95.7% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (37)
EPS (ttm)
-5.17
Sales (ttm)
730.0M
Net income (ttm)
-524.0M
Sales growth
+20.2%
EPS growth
-
Sales Q/Q
+8.1%
Free cash flow
-442.0M
Gross margin
-
Oper. margin
-64.0%
Net margin
-71.8%
FCF margin
-60.5%
ROE
n/m
R&D / sales
111.4%
Dividend
-
Debt/Eq
n/m
Curr. ratio
1.40
Cash
150.0M
Op. cash flow (ttm)
-437.0M
EBITDA
-500.0M
EBITDA margin
-74.3%
Quick ratio
1.26
FCF after stock pay
-625.0M
Goodwill / assets
2.9%
Oper. margin low 5y
-178.6%
Stock pay / sales
22.7%
Shares out.
101.9M
Shares Y/Y
+9.0%
Book / share
-3.69
Cash / share
1.47
Sales / share
7.16
Asset turnover
0.61
Days sales out.
86
Sales 3Y CAGR
+22.8%
Sales 5Y CAGR
+20.0%
Employees
1,371
Sales / employee
532K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 673.0M +158.0% a year Net income -575.0M
FY2016 revenue 133K · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-003324 FY2016 net income -245.9M · NetIncomeLoss, 0001564590-19-003324 133K FY2016 FY2017 revenue 2.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-004667 FY2017 net income -302.1M · NetIncomeLoss, 0001564590-20-004667 2.6M FY2017 FY2018 revenue 51.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-005610 FY2018 net income -197.6M · NetIncomeLoss, 0001564590-21-005610 51.5M FY2018 FY2019 revenue 103.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-22-001284 FY2019 net income -402.7M · NetIncomeLoss, 0000950170-22-001284 103.7M FY2019 FY2020 revenue 271.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-23-003096 FY2020 net income -186.6M · NetIncomeLoss, 0000950170-23-003096 271.0M FY2020 FY2021 revenue 351.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-017879 FY2021 net income -454.0M · NetIncomeLoss, 0000950170-24-017879 351.4M FY2021 FY2022 revenue 363.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-023312 FY2022 net income -707.4M · NetIncomeLoss, 0000950170-25-023312 363.3M FY2022 FY2023 revenue 434.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-057329 FY2023 net income -607.0M · NetIncomeLoss, 0001193125-26-057329 434.0M FY2023 FY2024 revenue 560.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-057329 FY2024 net income -569.0M · NetIncomeLoss, 0001193125-26-057329 560.0M FY2024 FY2025 revenue 673.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-057329 FY2025 net income -575.0M · NetIncomeLoss, 0001193125-26-057329 673.0M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $951.0M
  • − All liabilities $1.6B
  • = Net current asset value -$654.0M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $80.0M
  • − Goodwill $44.0M
  • − Other intangible assets $176.0M
  • = Tangible book value -$300.0M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

RARE against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+20.2%39th of 155 · median +10.5%
Net margin
-4.1%15.3%
-71.8%142nd of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
-60.5%133rd of 145 · median 10.0%
RARE and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
RARE Ultragenyx Pharmaceutical Inc.$730.0M +20.2%--71.8%--60.5%-
RGEN Repligen Corp$805.6M +16.4%53.5%-1.5%-0.6%13.2%0.27
TMDX TransMedics Group, Inc.$727.6M +37.1%58.6%19.9%26.2%6.1%-
GKOS GLAUKOS Corp$690.3M +32.3%64.8%-24.6%-23.7%5.2%-
TARS Tarsus Pharmaceuticals, Inc.$682.2M +147%--102.9%-4.8%0.70
MIRM Mirum Pharmaceuticals, Inc.$670.8M +54.7%--134.8%--40.8%-
All 162 companies in the group

Where the $673.0M of revenue came from

by product, year to Dec 31, 2025

  • Product Revenue $369.0M · 55%
  • Royalty revenue $304.0M · 45%

From the segment tables in the 10-K XBRL.

Profitability

  • Net margin below the peer median
    -71.8% vs 6.8%
  • A profit in 0 of 10 years
Net margin, FY2016 to FY2025: -184867.7% to -85.4%

Cash and shareholders

  • Free cash flow positive in 0 of 10 years
    −$472.0M last year
  • Share count up over 5 years
    +62.0%
Free cash flow, FY2016 to FY2025: -171.2M to -472.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

RARE's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue673.0M
FY2016: 133KFY2017: 2.6MFY2018: 51.5MFY2019: 103.7MFY2020: 271.0MFY2021: 351.4MFY2022: 363.3MFY2023: 434.0MFY2024: 560.0MFY2025: 673.0M FY2017FY2019FY2021FY2023FY2025
Net income-575.0M
FY2016: -245.9MFY2017: -302.1MFY2018: -197.6MFY2019: -402.7MFY2020: -186.6MFY2021: -454.0MFY2022: -707.4MFY2023: -607.0MFY2024: -569.0MFY2025: -575.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow-472.0M
FY2016: -171.2MFY2017: -256.6MFY2018: -294.6MFY2019: -370.2MFY2020: -176.1MFY2021: -411.8MFY2022: -496.6MFY2023: -519.0MFY2024: -421.0MFY2025: -472.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-625.0M
FY2016: -219.5MFY2017: -324.6MFY2018: -374.7MFY2019: -452.2MFY2020: -261.9MFY2021: -516.8MFY2022: -627.0MFY2023: -654.0MFY2024: -579.0MFY2025: -625.0M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-5.83
FY2016: -6.21FY2017: -7.12FY2018: -3.97FY2019: -7.12FY2020: -3.07FY2021: -6.70FY2022: -10.12FY2023: -8.25FY2024: -6.29FY2025: -5.83 FY2017FY2019FY2021FY2023FY2025
Diluted shares98.6M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 60.8MFY2021: 67.8MFY2022: 69.9MFY2023: 73.5MFY2024: 90.5MFY2025: 98.6M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Product Revenue 369.0M54.8% +29.5%
Royalty revenue 304.0M45.2% +10.5%
Collaboration and license 00.0% -

10-K 0001193125-26-057329, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
North America 377.0M56.0% +10.9%
Latin America 170.0M25.3% +29.8%
Europe, Middle East, and Africa 108.0M16.0% +35.0%
Asia-Pacific 18.0M2.7% +100%

10-K 0001193125-26-057329, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue133K2.6M51.5M103.7M271.0M351.4M363.3M434.0M560.0M673.0M
Cost of revenue-1K1.1M-------
R&D183.2M231.6M294.0M357.4M412.1M497.2M705.8M648.0M698.0M750.0M
SG&A64.9M99.9M127.7M161.5M182.9M220.0M278.1M310.0M321.0M349.0M
Operating income-248.0M-328.9M-371.4M-424.2M-330.1M-381.7M-648.9M-569.0M-536.0M-535.0M
Pretax income-245.8M-318.3M-197.1M-399.4M-185.4M-453.0M-701.7M-609.0M-567.0M-571.0M
Income tax35K-16.2M514K3.3M1.2M1.0M5.7M-2.0M2.0M4.0M
Net income-245.9M-302.1M-197.6M-402.7M-186.6M-454.0M-707.4M-607.0M-569.0M-575.0M
EPS (diluted)-6.21-7.12-3.97-7.12-3.07-6.70-10.12-8.25-6.29-5.83
Diluted shares----60.8M67.8M69.9M73.5M90.5M98.6M
Depreciation & amortization3.4M5.8M19.5M8.5M12.3M13.2M18.2M26.0M36.0M35.0M
EBITDA-244.6M-323.1M-351.8M-415.6M-317.9M-368.5M-630.7M-543.0M-500.0M-500.0M
Operating margin-186471.4%-12593.5%-721.2%-409.0%-121.8%-108.6%-178.6%-131.1%-95.7%-79.5%
Net margin-184867.7%-11567.3%-383.7%-388.3%-68.8%-129.2%-194.7%-139.9%-101.6%-85.4%
Revenue growth-+1864%+1871%+101%+161%+29.7%+3.4%+19.5%+29.0%+20.2%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-161.0M-253.8M-290.6M-345.4M-132.2M-338.7M-380.5M-475.0M-414.0M-466.0M
Capital spending10.2M2.8M4.1M24.8M43.9M73.1M116.1M44.0M7.0M6.0M
Free cash flow-171.2M-256.6M-294.6M-370.2M-176.1M-411.8M-496.6M-519.0M-421.0M-472.0M
Stock-based pay (added back)48.3M68.0M80.1M82.0M85.7M105.0M130.4M135.0M158.0M153.0M
Free cash flow after stock pay-219.5M-324.6M-374.7M-452.2M-261.9M-516.8M-627.0M-654.0M-579.0M-625.0M
Acquisitions-142.8M--0075.0M00-
Investing cash flow91.1M55.5M-33.3M-13.0M-179.1M-195.4M-291.7M168.0M-18.0M236.0M
Financing cash flow138.7M136.3M336.9M679.3M600.3M118.6M501.2M388.0M399.0M478.0M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)48.3M68.0M80.1M82.0M85.7M105.0M130.4M135.0M158.0M153.0M
Stock-based pay / revenue36322.6%2603.9%155.6%79.1%31.6%29.9%35.9%31.1%28.2%22.7%
Operating lease cost---9.2M10.2M11.2M11.8M13.0M12.0M12.0M
Operating lease cash paid---9.0M10.3M11.8M13.1M13.0M16.0M14.0M
Right-of-use assets---30.3M40.5M34.9M26.0M23.9M26.0M23.0M
Operating lease liabilities---37.0M47.1M41.0M31.4M43.2M40.3M36.0M
Finance lease liabilities----1.2M978K183K---

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.